摘要
目的:基于医疗保险数据,比较舒肝宁注射液和还原型谷胱甘肽注射液治疗肝胆疾病患者的经济负担。方法:利用中国医疗保险研究会(China Health Insurance Research Association,CHIRA) 2013年和2014年的抽样医疗保险数据库,选取肝癌、病毒性肝炎、肝纤维化和肝硬变、胆囊、胆道和胰腺目标疾病的病历资料,对其中使用舒肝宁注射液(舒肝宁组)和还原型谷胱甘肽注射液(还原型谷胱甘肽组)治疗患者的医疗费用进行回顾性研究,观察比较两组患者的基本特征以及全因住院时间、因目标疾病住院次数、出院半年内人均门诊次数、出院半年内返院率、全年人均医疗费用、次均就诊费用、次均住院费用。结果:最终纳入舒肝宁组和还原型谷胱甘肽组的样本量分别为1 201例和1 137例,两组患者基线特征比较差异均无统计学意义(均P> 0. 05)。从全因住院情况来看,舒肝宁组和还原型谷胱甘肽组患者的全因住院率比较,差异无统计学意义(P> 0. 05);但次均住院时间比较,舒肝宁组患者高于还原型谷胱甘肽组,差异有统计学意义(P <0. 05)。从因目标疾病住院情况来看,舒肝宁组患者住院率低于还原型谷胱甘肽组,且舒肝宁组患者2次以上住院率也低于还原型谷胱甘肽组,差异均有统计学意义(P <0. 05);但两组患者的半年内住院次数、出院半年内人均门诊次数、出院半年内返院率比较,差异均无统计学意义(P> 0. 05)。全年人均医疗费用、次均就诊(包含门诊和住院)费用、次均住院费用,两组比较差异均无统计学意义(P> 0. 05)。结论:与还原型谷胱甘肽注射液相比,舒肝宁注射液未过多占用肝胆疾病治疗的医疗资源,未加重肝胆疾病患者的经济负担,反而减少了患者的住院次数,给临床医师和患者提供了一个治疗选择。
Objective:To compare the economic burdens of patients with hepatobiliary diseases treated with Shuganning injection and reduced glutathione injection based on medical insurance datad.Methods:The China Health Insurance Research Association (CHIRA)2013 and 2014 sample medical insurance database was used to select medical records for liver cancer,viral hepatitis,liver fibrosis and cirrhosis,gallbladder,biliary and pancreatic diseases.The medical expenses of patients treated with Shuganning injection (shuganing group)and reduced glutathione injection (reduced glutathione group)were retrospectively analyzed.The basic characteristics and all-cause hospitalization time,the number of hospitalizations due to target diseases number of outpatient visits within half a year after discharge,rate of return to hospital within half a year of discharge,annual per capita medical expenses,secondary medical expenses,and average hospitalization expenses were compared.Results:The sample sizes of Shuganing group and reduced glutathione group were 1 201 and 1 137,respectively.There was no significant difference in the baseline characteristics between the two groups (P>0.05).From the all-cause hospitalization, there was no significant difference in the all-cause hospitalization rate between the Shuganning group and the reduced glutathione group (P>0.05).However,the average hospitalization time in the patients in the Shuganning group was higher than that in the reduced glutathione group,and the difference was statistically significant (P<0.05).For the hospitalization of the target diseases,the hospitalization rate of the Shuganning group was lower than that ofthe reduced glutathione group,and the rate of hospitalization for no less than two times in the Shuganing group was lower than that in the reduced glutathione group (P<0.05);however,the number of hospitalizations,the number of outpatient visits within half a year after discharge,and the rate of return to hospital within half a year after discharge were not statistically significant be
作者
冯鑫
杨雪莲
FENG Xin;YANG Xue-lian(China Medical Insurance Research Association,Beijing 100013,China;Beijing BoRuiTongXin Consultation Ltd.,Beijing 100021,China)
出处
《中国新药杂志》
CAS
CSCD
北大核心
2018年第24期2962-2968,共7页
Chinese Journal of New Drugs
